BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a company name.

Mediolanum Farmaceutici S.p.A.

Headquarters: Milan, Italy
Year Founded: 1972
Status: Private

BioCentury | Aug 27, 2020
Distillery Therapeutics

A collagen receptor as an Alzheimer’s target

DISEASE CATEGORY: Neurology
INDICATION: Alzheimer’s disease (AD) Blocking the collagen receptor GP6 could treat Alzheimer’s disease by reducing platelet-associate β amyloid
BioCentury | Nov 18, 2016
Company News

Acticor, Mediolanum deal

BioCentury | Mar 2, 2015
Company News

Panoptes Pharma, Mediolanum Farmaceutici deal

BioCentury | May 13, 2013
Emerging Company Profile

Ultimovacs: hTERT redux

Ultimovacs targeting multiple epitopes on the cancer target telomerase
BioCentury | Dec 10, 2012
Company News

Genovax, Mediolanum Farmaceutici deal

Items per page:
1 - 5 of 5